DoD Prostate Cancer, Idea Development Award | HT942524PCRPIDA

FAQs: FY24 DoD Prostate Cancer Research Program (PCRP) Idea Development Award (HT942524PCRPIDA)

1) What is the FY24 PCRP Idea Development Award?

The FY24 Department of Defense (DoD) Prostate Cancer Research Program (PCRP) Idea Development Award is a discretionary grant opportunity run through the U.S. Army Medical Research Acquisition Activity (USAMRAA). It supports bold, original prostate cancer research concepts that introduce genuinely new ways of thinking or new methods, rather than incremental extensions of existing work.

2) Who runs and administers this funding opportunity?

This opportunity is administered through USAMRAA under the DoD PCRP.

3) What are the identifying numbers for this opportunity?

Funding Opportunity Number (FON): HT942524PCRPIDA. CFDA: 12.420.

4) What type of award instrument is used?

The mechanism uses a grant instrument under 31 USC 6304.

5) Who is eligible to apply?

The program is described as open to unrestricted eligible applicants. Specific eligibility rules, including those for the New Investigator category, are referenced as being detailed in the full announcement.

6) What kinds of projects does the award want to fund?

The award is designed for high-risk, high-reward prostate cancer research that is innovative and creative. Competitive proposals are expected to challenge existing assumptions, propose new paradigms, or reframe persistent problems in prostate cancer from a fresh angle.

7) What does the program mean by "innovation" in this context?

Innovation is a central priority. The opportunity explicitly signals that simply extending published work in a straightforward way is not considered innovative. Strong applications should show genuine originality, such as new concepts, new frameworks, or new methods that could meaningfully advance the PCRP mission.

8) Are multidisciplinary projects encouraged?

Yes. Multidisciplinary approaches are encouraged, including projects integrating data science, bioinformatics, mathematical modeling, and other cross-cutting methods.

9) Are there specific study populations or resources the program is interested in?

The program is welcoming to projects that leverage unusual or uniquely informative study populations. It also encourages projects that capitalize on large existing patient datasets and resources, including efforts that combine long-term health records, biorepositories, and pre-existing studies with modern genomics/proteomics and advanced analytics.

10) What is meant by "impact" for this award?

Impact is a major theme. Applicants are expected to clearly connect the project to one or more FY24 PCRP Overarching Challenges and explain how the work could address those challenges. Reviewers will look for near-term value during the award period (such as a validated model, robust dataset, or new diagnostic approach) and long-term value (how success could shift the field or improve patient care).

11) Do applicants need to address the FY24 PCRP Overarching Challenges?

Yes. Applicants must connect their proposed work to one or more FY24 PCRP Overarching Challenges and explain, in concrete terms, how the research could address them.

12) Is preliminary data required?

No. Preliminary data are optional. The mechanism is intended to encourage high-risk, high-reward ideas, so preliminary results are encouraged but not required.

13) If preliminary data are included, are there expectations about where the data come from?

Yes. If unpublished preliminary data are included, they are expected to come from the Principal Investigator (PI) or members of the proposing team.

14) If preliminary data are not required, what does the application need to be credible?

Even speculative ideas must have a sound scientific rationale supported by logical reasoning and/or careful reading of existing literature, along with a clear plan to test the concept.

15) Is there a New Investigator category?

Yes. A distinct New Investigator category is included to support investigators early in their independent careers. New Investigator applications are reviewed with different personnel criteria and must meet specific eligibility rules described in the full announcement.

16) What extra team requirements apply to New Investigator applications?

New Investigator applications must include at least one collaborator with demonstrated prostate cancer research experience, supported by a track record of funding and publications. The proposal must explain why the collaboration is likely to work, how collaborators strengthen the team, and how they fill gaps in the new PI's expertise.

17) Are letters of collaboration or support required?

The program strongly encourages letters of collaboration that describe the collaborator's role and level of commitment, especially for New Investigator applications. Letters of support demonstrating access to key resources are also strongly encouraged when resource availability could be a limiting factor.

18) Are multi-institutional projects allowed?

Yes. The award supports multidisciplinary and multi-institutional projects, but emphasizes planning for teamwork and execution.

19) What must multi-institutional applications include to show the collaboration will work?

Applications spanning multiple organizations must include an interaction plan describing how communication will occur, how progress will be coordinated, how results will be shared, and how data will be transferred.

20) Is an intellectual property (IP) plan required for multi-institutional proposals?

Multi-institutional proposals must address intellectual property considerations with an IP plan intended to avoid institutional barriers that could slow collaboration or threaten successful completion of the project.

21) What does the program expect regarding rigor and reproducibility?

The program encourages rigorous and reproducible practices. Where relevant, investigators are encouraged to authenticate cell lines, ensure statistical rigor in animal and preclinical studies, and include experiments that address clinical relevance and translational potential.

22) Are there specific study design practices the announcement highlights?

Yes. The announcement highlights transparent reporting and good experimental design principles aligned with Landis et al. (Nature, 2012), including randomization, blinding, sample size estimation, and clear data handling practices.

23) Does the program encourage leveraging existing datasets and infrastructure?

Yes. The program encourages use of large existing patient datasets and resources, especially those integrating health records, biorepositories, and pre-existing studies with genomics/proteomics and advanced analytics.

24) How should applicants address access to essential datasets, repositories, or infrastructure?

When a project depends on specialized datasets, repositories, or unique infrastructure, the application should document that access exists at submission and include a plan to maintain that access throughout the work.

25) Are there program areas of special interest mentioned in the announcement?

Yes. The announcement encourages applicants to consider recommendations from the congressionally mandated Metastatic Cancer Task Force when aligned with PCRP priorities and within the boundaries of this mechanism. It also explicitly welcomes innovative prostate cancer research involving nuclear medicine and related techniques, including noninvasive precision imaging and targeted therapy approaches, particularly those that could improve outcomes for active-duty Service Members and their families.

26) Does the opportunity encourage partnerships across sectors?

Yes. The program encourages collaboration among academia, industry, military services, the Department of Veterans Affairs, and other federal agencies, noting that these partnerships can provide unique infrastructure and access to distinct clinical populations that may accelerate progress for Service Members, Veterans, and their families.

27) Are clinical trials allowed under this award?

No. Clinical trials are not allowed under this award, using the federal definition at 45 CFR 46.102 (human subjects prospectively assigned to an intervention to evaluate effects on health-related outcomes).

28) What kinds of human-focused research are allowed if clinical trials are prohibited?

The award allows certain types of clinical research that are observational or otherwise do not evaluate an intervention's safety or efficacy. Examples listed include studies of disease mechanisms in humans, diagnostic or detection studies (including biomarkers or imaging), health disparity research, technology development, epidemiology and behavioral studies that do not test an intervention, and outcomes or health services research that does not meet the clinical trial definition.

29) How does the announcement treat in vitro studies using human data or specimens?

The announcement notes that some in vitro studies using human data/specimens may fall outside the definition of clinical research if they cannot be linked to living individuals and meet specific Common Rule exemption conditions.

30) What is the maximum direct cost amount applicants should plan for?

Applicants should plan for total direct costs across the full performance period of no more than $1.2 million.

31) How much total funding does DoD expect to allocate, and how many awards are anticipated?

The DoD expects to allocate about $53.76 million total to support roughly 28 awards. Actual funding depends on federal funds availability, application volume, and the outcomes of peer and programmatic review.

32) What is the application closing date listed in the information provided?

The original application closing date listed is July 19, 2024.

33) By when are awards expected to be made?

Awards using FY24 funds are expected to be made no later than September 30, 2025.

34) How long are FY24 funds expected to remain available for use?

FY24 funds are anticipated to remain available for use until September 30, 2030. This relates to the government obligation window, while project timelines are governed by the individual award terms.

35) What overall message does the program communicate about balancing innovation and credibility?

The program emphasizes that even highly innovative, creative ideas must be designed so findings are credible, reproducible, and useful for eventual translation. Applications should pair originality with strong rationale, clear test plans, and rigorous study practices.